Candriam Luxembourg S.C.A. lifted its holdings in shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) by 20.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,000 shares of the biopharmaceutical company’s stock after purchasing an additional 5,000 shares during the period. Candriam Luxembourg S.C.A. owned 0.11% of GW Pharmaceuticals PLC worth $2,943,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in GWPH. Janus Henderson Group PLC bought a new stake in shares of GW Pharmaceuticals PLC during the 2nd quarter valued at about $70,128,000. Pictet Asset Management Ltd. boosted its position in shares of GW Pharmaceuticals PLC by 102.6% during the 3rd quarter. Pictet Asset Management Ltd. now owns 355,263 shares of the biopharmaceutical company’s stock valued at $36,056,000 after purchasing an additional 179,911 shares in the last quarter. Redmile Group LLC boosted its holdings in GW Pharmaceuticals PLC by 33.8% in the second quarter. Redmile Group LLC now owns 444,936 shares of the biopharmaceutical company’s stock worth $44,605,000 after acquiring an additional 112,392 shares in the last quarter. Renaissance Technologies LLC bought a new position in GW Pharmaceuticals PLC in the first quarter worth approximately $10,909,000. Finally, Employees Retirement System of Texas bought a new position in GW Pharmaceuticals PLC in the second quarter worth approximately $5,313,000. Institutional investors own 75.71% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “GW Pharmaceuticals PLC (GWPH) Shares Bought by Candriam Luxembourg S.C.A.” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.watchlistnews.com/gw-pharmaceuticals-plc-gwph-shares-bought-by-candriam-luxembourg-s-c-a/1706923.html.

Several research analysts have issued reports on GWPH shares. Zacks Investment Research lowered GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Maxim Group set a $135.00 price objective on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Monday, August 7th. Cantor Fitzgerald set a $208.00 price objective on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Leerink Swann reissued an “outperform” rating and issued a $160.00 price objective (down from $162.00) on shares of GW Pharmaceuticals PLC in a research note on Thursday, August 10th. Finally, BidaskClub downgraded GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $144.55.

GW Pharmaceuticals PLC (NASDAQ:GWPH) opened at $117.22 on Thursday. GW Pharmaceuticals PLC has a twelve month low of $92.65 and a twelve month high of $136.95. The company has a current ratio of 10.39, a quick ratio of 10.26 and a debt-to-equity ratio of 0.02.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC (NASDAQ:GWPH).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.